News Category
Onco-Innovations Limited has signed a letter of intent to potentially acquire an exclusive option on Ifowonco's oral small-molecule LAG-3 inhibitor pr...
Creative Biolabs has expanded its complement assay service portfolio, offering customizable solutions like C3b deposition and hemolytic inhibition ass...
Quantum BioPharma's Lucid-MS offers a novel approach to multiple sclerosis by targeting myelin degradation and smoldering lesions, potentially address...
Silo Pharma's receipt of a Canadian patent allowance for its lead PTSD asset SPC-15 strengthens its global IP portfolio and supports its strategic use...
Quantum BioPharma's myelin-protecting therapy Lucid-MS, now FDA-cleared for Phase 2 trials, represents a paradigm shift in MS treatment from immune su...
Regentis Biomaterials' new patent for its solvent-free manufacturing process strengthens its IP portfolio and supports scaling up production of its of...
VERAXA Biotech's collaboration with Ardigen aims to use AI to identify optimal dual-target combinations for cancer therapies, potentially reviving aba...
VERAXA Biotech's collaboration with Ardigen aims to use AI to optimize its BiTAC platform, potentially improving target validation and reducing develo...
The American Heart Association's 2026 Health Tech Competition is now accepting applications to bridge the gap between promising health technologies an...
Researchers have identified a protein on glioblastoma cells that, when targeted, could make the cancer more vulnerable to existing treatments, potenti...
NanoViricides expects to begin a Phase II clinical trial of its oral antiviral NV-387 for Ebola in the Democratic Republic of Congo, highlighting a po...
Helus Pharma's appointments of Regina Donohue as Chief People Officer and Suresh Durgam to its Scientific Advisory Board signal strategic preparation ...
Cayenne Wellness Center's 20th Annual Sickle Cell Disease Educational Summit, themed '20/20 Vision: Our Legacy Continues,' underscores two decades of ...
Helix BioPharma strengthens its leadership with the appointment of Dr. Markus Loeffler as CMO to guide its oncology pipeline through upcoming clinical...
Quantum BioPharma reported reduced Q2 expenses and FDA clearance to start Phase 2 trials for its multiple sclerosis drug, positioning the company for ...
Regentis Biomaterials is simultaneously progressing its GelrinC cartilage repair implant through a pivotal US Phase III trial and European commercial ...
Alpha Cognition's Q2 2026 earnings show ZUNVEYL demand accelerating, with net product revenue up 71% quarter-over-quarter, despite payer access still ...
Two young scientists receive $200,000 each to pursue innovative research on lung cancer early detection and drug resistance, highlighting the critical...
PX1 Research's new seven-stage testing protocol for domestically manufactured research peptides ensures 99%+ purity with full documentation, addressin...
A comprehensive review in World Journal of Pediatric Surgery synthesizes evidence on surgical management of NEC, emphasizing bowel preservation and in...
Onco-Innovations is building the manufacturing and scientific foundation for its nanoparticle-encapsulated PNKP inhibitor ONC010, aiming to advance bi...
Regentis Biomaterials' GelrinC hydrogel implant gains European approval for scalable manufacturing, positioning it to disrupt the multi-billion knee c...
Researchers at the University of Manchester found that a small group of immune cells, previously understudied, plays a crucial role in mobilizing the ...
Quantum BioPharma reported reduced Q2 expenses and received FDA approval for its Phase 2 trial of Lucid-MS, a potential treatment for progressive mult...
Regentis Biomaterials is strategically advancing its cartilage repair product GelrinC through parallel U.S. clinical trials and European commercializa...
Lantern Pharma reported Q2 2026 results highlighting pipeline progress and the establishment of Open Medicine AI as a separate company, marking a stra...
Helus Pharma's completion of enrollment in its pivotal Phase 3 APPROACH trial for HLP003 in major depressive disorder brings the company closer to a p...
DM Clinical Research celebrates its 20th anniversary, highlighting its growth into a leading clinical research network with over 35 sites and 35,000 p...
NeOnc Technologies' NEO100 meets primary endpoint in Phase 2a for recurrent brain cancer, with survival signals and FDA alignment advancing both NEO10...
PX1 Research's new batches of Retatrutide and Tirzepatide peptides, manufactured in USA cGMP facilities with HPLC batch verification, ensure high puri...
Quantum BioPharma's Lucid-MS focuses on inhibiting myelin degradation to address progression independent of relapse activity, a key driver of long-ter...
GeoVax emphasizes the potential of its MVA-based vaccine candidates and expertise to contribute to the global response against the escalating Bundibug...
Drugmakers are investing approximately $500 billion in the U.S. to avoid planned tariffs, which could reshape the pharmaceutical landscape and impact ...
Nutriband's CEO will present at the 2026 Georgia Life Sciences Summit, underscoring the company's commitment to addressing opioid abuse through its AV...
Quantum BioPharma's FDA approval to advance Lucid-MS into Phase 2 trials marks a significant step toward a potential disease-modifying therapy for mul...
PX1 Research launches a line of US-manufactured sublingual peptide strips for needle-free research, featuring Retatrutide, Tirzepatide, and BPC-157 wi...
PX1 Research's expanded cGMP quality control and seven-stage HPLC purity verification ensure 99%+ purity for research peptides, providing batch-specif...
NanoViricides has received regulatory approval to begin a Phase II clinical trial of its oral antiviral NV-387 for Ebola in the Democratic Republic of...
New research from the University of Virginia suggests focused ultrasound could make brain cancer treatments more effective and less harmful, potential...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn suppresses tumor growth in TNBC models, providing the scientific f...
Quantum BioPharma's FDA approval to begin Phase 2 trials for Lucid-MS, a novel neuroprotective candidate for multiple sclerosis, marks a significant s...
Tonix Pharmaceuticals' second-quarter 2026 results show a dramatic revenue increase driven by TONMYA, highlighting the drug's commercial success and t...
Tonix Pharmaceuticals' Q2 revenue surged to $13.5 million, driven by TONMYA sales, signaling strong market uptake and positioning the company for cont...
Tonix Pharmaceuticals' Q2 2026 revenue surged to $13.5 million, driven by TONMYA sales, signaling commercial success and pipeline progress.
A new narrative review in the World Journal of Pediatric Surgery provides a comprehensive framework for risk-adapted diagnosis and treatment of neurob...
Regentis Biomaterials progresses its GelrinC cartilage regeneration technology through U.S. clinical trials, FDA submission preparation, European comm...
Quantum BioPharma is progressing its two-pronged approach to neurological health, targeting multiple sclerosis with Lucid-MS and alcohol misuse with u...
Quantum BioPharma is advancing its investigational MS therapy Lucid-MS and its supplement unbuzzd, targeting neurological health through distinct mech...
